This multi-center study of 511 adults with acute myeloid leukemia (AML) showed that FLT3 mutation status had no effect on non-relapse mortality (NRM), leukemia-free survival (LFS), or overall survival (OS) after hematopoietic cell transplantation (HCT). Researchers studying data reported to CIBMTR (Center for International Blood and Marrow Transplant Research) found that although HCT recipients with FLT3 mutations had higher rates of relapse at 3 years compared to wild type FLT3 patients (38% vs. 28%, respectively; p=0.04), three-year OS was comparable (49%, vs. 55%, respectively; p=0.20). FLT3 mutation status was not significantly associated with NRM or LFS. The authors concluded that “HCT may be able to overcome the prognostic impact of FLT3 mutations in AML with promising LFS and OS.”
FLT3 Mutation Has No Effect on Survival in HCT for AML
Jul 2016